Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Fosamprenavir (Lexiva, FPV)
Last Updated: December 7, 2018; Last Reviewed: December 7, 2018
Excerpt from Table 8
|Formulation||Dosing Recommendationsa||Use in Pregnancy|
Lexiva (a prodrug of amprenavir)
Note: Must be combined with low-dose RTV boosting in pregnancy
|Standard Adult Doses
PK in Pregnancy:
Dosing in Pregnancy:
FPV should not be used during pregnancy.
Insufficient data to assess for teratogenicity in humans. Increased fetal loss in rabbits but no increase in defects in rats and rabbits.
a Individual ARV drug dosages may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the Adult and Adolescent Guidelines Appendix B, Table 7).
Key to Acronyms: ARV= antiretroviral; AUC= area under the curve; EFV = efavirenz; FPV = fosamprenavir; PI = protease inhibitor; PK = pharmacokinetic; RTV = ritonavir
- AIDSinfo Drug Database
- AIDSinfo Patient Materials: Preventing Mother-to-Child Transmission of HIV
- AIDSinfo Patient Materials: HIV Medicines During Pregnancy and Childbirth
- AIDSinfo Patient Materials: Protecting Baby from HIV
- AETC National HIV Curriculum
- How to Cite These Guidelines
- Perinatal Guidelines Archive